Understanding Series

The IMF's Understanding series of booklets is designed to acquaint you with treatments and supportive care measures for multiple myeloma. These booklets are also available by mail order and communicate information in a format that is easy to read and understand.

Order Print Edition

Understanding Thalidomide Therapy
July 31, 2018

Thalidomide is an oral immunomodulatory drug that is widely used throughout the myeloma disease course in the frontline, consolidation/maintenance, and relapse settings. Immunomodulatory drugs induce immune responses, enhance the activity of immune cells, and inhibit inflammation by altering the levels of various growth factors.

Understanding Treatment of Myeloma-Induced Vertebral Compression Fractures
May 18, 2018

As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress placed upon it.

Understanding VELCADE® (bortezomib) for Injection
May 18, 2018

Velcade® (bortezomib) is a proteasome inhibitor that plays a role throughout the myeloma disease course, from induction therapy for the newly diagnosed, to a possible role as part of conditioning for stem cell transplant, to consolidation/maintenance therapy, to treatment for those whose myeloma has relapsed or become refractory.

Understanding Your Test Results
July 03, 2018

This booklet outlines the tests that are used to diagnose and monitor myeloma, and to detect response and relapse. No single study is adequate to tell the whole story about a patient’s status but, used together, test results give a more complete picture.